La cadena de opciones muestra datos clave de las opciones de acciones de Accolade Inc Ordinary Shares a varios precios de ejercicio y fechas de vencimiento. Los operadores utilizan esta información para analizar posibles operaciones y evaluar el sentimiento del mercado para Accolade Inc Ordinary Shares..

Accolade Inc Ordinary Shares (NASDAQ:ACCD) Bolsa, Cadena de Opciones

Accolade

Equities

News

Markets

ETFs

ACCD

ARKW

ESLT

HOOD

Ark Invest vende acciones de Robinhood en medio de desafíos económicos y oportunidades regulatorias. Descubre las claves de este movimiento.

Ark Invest vende acciones de Robinhood (HOOD): Impacto en el mercado y ajustes clave del portafolio

ABSI

ARKG

ARKK

ARKQ

ARKX

ILMN

NTLA

OKLO

PATH

Descubre las recientes decisiones de Ark Invest en energía, defensa y genética, con transacciones millonarias en empresas clave.

Ark Invest adquiere y vende acciones clave en energía, defensa y tecnología genética

Accolade Inc Ordinary Shares

Marvell Tech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRVL#NASDAQ">MRVL</a>) has outperformed the market over the past 10 years by 3.77% on an annualized basis producing an average annual return of 13.36%. Currently, Marvell Tech has a market capitalization of $44.78 billion. 
Buying $100 In MRVL: If an investor had bought $100 of MRVL stock 10 years ago, it would be worth $346.05 today based on a price of $51.70 for MRVL at the time of writing.
<h3>Marvell Tech's Performance Over Last 10 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1744924532_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Trading Ideas

MRVL

$100 Invested In Marvell Tech 10 Years Ago Would Be Worth This Much Today

Roku Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ROKU#NASDAQ">ROKU</a>) shares are rising in extended trading Thursday following strong advertising trends from Netflix Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NFLX#NASDAQ">NFLX</a>), which reported blowout results for the <a href="https://www.benzinga.com/general/entertainment/25/04/44877995/netflix-crushes-q1-says-its-working-hard-to-improve-and-expand-its-offering">first quarter after the bell</a>.
Netflix Q1 Results: Netflix reported first-quarter revenue of $11.04 billion, beating analyst estimates of $10.9 billion, according to <a href="http://pro.benzinga.com">Benzinga Pro</a>. The streaming giant reported adjusted earnings of $7.03 per share, beating estimates of $6.27 per share. 
Total revenue was up 13% year-over-year, driven by membership growth and higher pricing. The company said results came in above company expectations due to higher-than-forecasted subscription and ad revenue. Netflix guided for 15% revenue growth in the second quarter, citing continued strong trends in memberships and advertising revenue. 
&#8220;A key focus in 2025 is enhancing our capabilities for advertisers. We successfully rolled out the Netflix Ads Suite, our in house first party ad tech platform, in the U.S. on April 1st. In the coming months we will launch the Netflix Ads Suite in our remaining ads markets. We believe our ad tech platform is foundational to our long-term ads strategy,&#8221; the company said in a letter to shareholders.
Everything You Need To Know: <a href="https://www.benzinga.com/general/entertainment/25/04/44877995/netflix-crushes-q1-says-its-working-hard-to-improve-and-expand-its-offering">Netflix Crushes Q1, Says It&#8217;s &#8216;Working Hard To Improve And Expand&#8217; Its Offering</a>
Why It Matters: Roku is well-positioned to benefit from strong advertising trends. The company focuses on revenue opportunities with streaming companies through partnerships and advertising. 
Netflix was reportedly&nbsp;<a href="https://www.benzinga.com/analyst-ratings/analyst-color/22/06/27622300/3-reasons-why-this-analyst-thinks-a-netflix-roku-deal-may-not-materialize" target="_blank" rel="noreferrer noopener">considering a takeover of Roku</a>&nbsp;a few years ago, but a deal never materialized. Roku operates an advertising distribution platform, allowing it to capitalize on the growth of streaming. 
Roku on Thursday announced it will report first-quarter earnings on May 1. Analysts are anticipating a loss of 27 cents per share and revenue of $1.01 billion, according to estimates from <a href="http://pro.benzinga.com">Benzinga Pro</a>.
Last quarter, Roku shares surged after the company reported better-than-expected results and crossed $1 billion in Platform revenue for the first time. 
&#8220;In&nbsp;Q4, Streaming Hours on The Roku Channel grew&nbsp;82%&nbsp;YoY, and in the U.S. it reached households with approximately 145 million people," the company said at the time. &#8220;We also continue to expand our penetration in the U.S., which has surpassed half of broadband households.&#8221;
ROKU Price Action: Roku shares initially popped about 2.5% following Netflix&#8217;s results. The stock was up 0.92% after-hours, trading at $59 at the time of publication Thursday, according to <a href="http://pro.benzinga.com">Benzinga Pro</a>.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/content/44861194/disney-how-the-fubo-sports-deal-became-a-game-changer">Disney: How the Fubo Sports Deal Became a Game Changer</a></li>
</ul>
Photo: <a href="https://www.shutterstock.com/g/tadaimages">Tada Images</a>/Shutterstock.

After-Hours Center

Movers

Media

NFLX

ROKU

Roku Stock Moves Higher Following Netflix Q1 Earnings: What You Need To Know

General

PCRX

Pacira BioSciences Announces $300M Share Repurchase Program

Bank of America Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BAC#NYSE">BAC</a>) is ramping up its <a href="https://www.benzinga.com/news/earnings/24/07/39801252/bofa-manages-to-keep-expenses-in-check-by-going-digital-now-the-bank-is-using-ai-to-take-it-to-anot">investment in artificial intelligence</a>, planning to spend $4 billion on AI initiatives over the next year—nearly a third of its annual $13 billion tech budget.
The company <a href="https://newsroom.bankofamerica.com/content/newsroom/press-releases/2025/04/ai-adoption-by-bofa-s-global-workforce-improves-productivity--cl.html">disclosed</a> the figure in a recent release, noting that both internal and customer-facing tools are already showing strong returns, ranging from cost reductions to improved user experiences.
Benzinga reached out to Bank of America for more details, but the bank was unable to comment by the time of publication. That being said, there are many interesting tidbits to highlight in the press release itself.
Among major U.S. banks, Bank of America appears to be leading the charge in deploying AI at scale. Its consumer chatbot Erica—launched seven years ago—has handled over 2.5 billion interactions and now serves 20 million active users. Meanwhile, sibling products like askMerrill and askPrivate Banking saw more than 23 million interactions in 2024, up by over a million from the previous year.
<h3 class="wp-block-heading">Enterprise AI Is Catching Up Fast</h3>
While consumer-facing AI has been in place for years, BofA's enterprise AI rollout is more recent—and more ambitious. New internal data reveals just how widely the bank is applying generative AI across its operations:
<ul>
<li>Internal Support (IT): Erica for Employees, an internal AI chatbot adapted from the public-facing version, is now used by over 90% of BofA's 213,000 employees—reducing IT help desk requests by more than 50%.</li>
<li>Developer Productivity: Engineers using generative AI coding assistants are seeing up to 20% improvements in productivity, helping them move faster across technical workflows.</li>
<li>Meeting Preparation: AI is helping employees generate meeting prep materials for client engagements, saving tens of thousands of hours annually—time that's redirected toward client-facing work.</li>
<li>Customer Support: Contact center agents use AI tools to deliver faster, more personalized service, which has reduced average call times.</li>
<li>Research Access (Sales &amp; Trading): Sales and trading teams use a homegrown generative AI tool to summarize BofA research and market updates more efficiently, helping them move quickly in volatile markets.</li>
</ul>
<h3 class="wp-block-heading">Why This Matters</h3>
Other institutions like JPMorgan Chase &amp; Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JPM#NYSE">JPM</a>), Goldman Sachs Group Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GS#NYSE">GS</a>), and Citigroup Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/C#NYSE">C</a>) are also building AI-powered tools for employees and customers. But Bank of America stands out for its transparency and measurable results.
Cutting IT support demand in half, improving developer velocity, and enhancing customer satisfaction are all indicators that this isn't hype—it's execution.
And yet, this is just the beginning. The generative AI transformation in banking is still in its early innings. What we're seeing now is likely just a preview of how financial services will operate in the next decade.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/04/44878275/billionare-investor-bill-ackman-posts-hertz-investment-thesis-proposes-av-fleet-partnership-with-uber">Billionare Investor Bill Ackman Posts Hertz Investment Thesis, Proposes AV Fleet Partnership With Uber</a></li>
</ul>
Photo: Shutterstock

Fintech news covering the emerging Financial Technology services sector

Fintech

Tech

Bank Of America Bets Big On AI With $4 Billion Investment—And It's Already Paying Off

NRGV

Energy Vault Holdings Receives Notice Regarding Continued Listing Standards From NYSE

<h3>Gainers</h3>
<ul>
<li>BitFuFu (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FUFU#NASDAQ">FUFU</a>) stock rose 17.1% to $5.05 during Thursday's after-market session. The market value of their outstanding shares is at $822.6 million. </li>
<li>Iveda Solutions (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IVDA#NASDAQ">IVDA</a>) stock increased by 6.19% to $2.57. The market value of their outstanding shares is at $6.8 million. The company's, Q4 earnings came out 2 days ago. </li>
<li>Soluna Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SLNH#NASDAQ">SLNH</a>) shares increased by 5.06% to $0.65. The market value of their outstanding shares is at $6.8 million. </li>
<li>SkyWater Technology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SKYT#NASDAQ">SKYT</a>) shares rose 4.85% to $6.91. The market value of their outstanding shares is at $331.6 million. </li>
<li>NOVONIX (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVX#NASDAQ">NVX</a>) shares increased by 4.23% to $1.23. The market value of their outstanding shares is at $195.5 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Fatpipe (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FATN#NASDAQ">FATN</a>) stock declined by 8.4% to $11.38 during Thursday's after-market session. The company's market cap stands at $156.1 million. </li>
<li>Smith Micro Software (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMSI#NASDAQ">SMSI</a>) shares declined by 6.48% to $0.86. The market value of their outstanding shares is at $15.2 million. </li>
<li>DoubleVerify Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DV#NYSE">DV</a>) shares decreased by 5.29% to $11.82. The company's market cap stands at $1.9 billion. </li>
<li>Peraso (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRSO#NASDAQ">PRSO</a>) stock declined by 5.0% to $0.66. The company's market cap stands at $2.5 million. </li>
<li>Saverone 2014 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SVRE#NASDAQ">SVRE</a>) stock declined by 4.91% to $1.94. The company's market cap stands at $1.1 million. </li>
<li>XIAO-I (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AIXI#NASDAQ">AIXI</a>) shares fell 4.07% to $2.83. The market value of their outstanding shares is at $29.8 million. 
See Also: <a href="http://www.benzinga.com/money/tech-stocks/" title="www.benzinga.com/money/tech-stocks/">www.benzinga.com/money/tech-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

AIXI

FATN

FUFU

IVDA

Nuveen California Dividend Advantage Municipal Fund 2

PRSO

SKYT

SLNH

SMSI

SVRE

11 Information Technology Stocks Moving In Thursday's After-Market Session

<h3>Gainers</h3>
<ul>
<li>Lobo EV Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LOBO#NASDAQ">LOBO</a>) stock rose 9.6% to $0.8 during Thursday's after-market session. The market value of their outstanding shares is at $6.9 million. </li>
<li>Mixed Martial Arts Group (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/MMA#AMEX">MMA</a>) shares rose 7.51% to $1.0. The company's market cap stands at $10.4 million. </li>
<li>Gogoro (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GGR#NASDAQ">GGR</a>) stock moved upwards by 7.5% to $0.31. The market value of their outstanding shares is at $90.4 million. </li>
<li>Thunder Power Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AIEV#NASDAQ">AIEV</a>) shares increased by 7.47% to $0.15. The market value of their outstanding shares is at $7.3 million. </li>
<li>Color Star Tech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADD#NASDAQ">ADD</a>) stock moved upwards by 7.16% to $0.83. </li>
<li>Birks Group (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/BGI#AMEX">BGI</a>) stock increased by 6.7% to $0.94. The market value of their outstanding shares is at $18.0 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Lixiang Education Hldg (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LXEH#NASDAQ">LXEH</a>) shares declined by 25.7% to $5.08 during Thursday's after-market session. The market value of their outstanding shares is at $5.9 million. </li>
<li>Kaixin Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KXIN#NASDAQ">KXIN</a>) stock fell 8.41% to $1.09. The market value of their outstanding shares is at $1.9 million. </li>
<li>Mingteng International (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MTEN#NASDAQ">MTEN</a>) shares declined by 5.22% to $4.0. The company's market cap stands at $27.3 million. </li>
<li>MEDIROM Healthcare Techs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRM#NASDAQ">MRM</a>) stock declined by 5.19% to $0.75. The market value of their outstanding shares is at $5.9 million. </li>
<li>Foresight Autonomous (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FRSX#NASDAQ">FRSX</a>) stock decreased by 5.14% to $0.6. The market value of their outstanding shares is at $11.3 million. </li>
<li>Jiuzi Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JZXN#NASDAQ">JZXN</a>) stock fell 4.92% to $6.38. The company's market cap stands at $70.2 million. 
See Also: <a href="http://www.benzinga.com/money/best-consumer-cyclical-stocks/" title="www.benzinga.com/money/best-consumer-cyclical-stocks/">www.benzinga.com/money/best-consumer-cyclical-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

AIEV

FRSX

JZXN

KXIN

LOBO

LXEH

MTEN

12 Consumer Discretionary Stocks Moving In Thursday's After-Market Session

<h3>Gainers</h3>
<ul>
<li>Direct Digital Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DRCT#NASDAQ">DRCT</a>) shares moved upwards by 51.6% to $0.97 during Thursday's after-market session. The company's market cap stands at $18.3 million. </li>
<li>Baosheng Media Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BAOS#NASDAQ">BAOS</a>) stock moved upwards by 17.64% to $2.0. The market value of their outstanding shares is at $3.0 million. </li>
<li>Intelligent Protection (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IPM#NASDAQ">IPM</a>) shares rose 7.18% to $1.79. The market value of their outstanding shares is at $16.5 million. </li>
<li>Treasure Global (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TGL#NASDAQ">TGL</a>) stock moved upwards by 5.3% to $2.98. The company's market cap stands at $4.8 million. </li>
<li>AirNet Technology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ANTE#NASDAQ">ANTE</a>) shares moved upwards by 4.72% to $0.78. The company's market cap stands at $11.1 million. </li>
<li>BloomZ (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BLMZ#NASDAQ">BLMZ</a>) shares increased by 4.47% to $0.15. The market value of their outstanding shares is at $2.1 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Super League Enterprise (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SLE#NASDAQ">SLE</a>) stock fell 6.4% to $0.22 during Thursday's after-market session. The market value of their outstanding shares is at $3.7 million. </li>
<li>Cumulus Media (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CMLS#NASDAQ">CMLS</a>) stock decreased by 5.01% to $0.24. The market value of their outstanding shares is at $4.0 million. </li>
<li>Liberty Latin America (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LILAK#NASDAQ">LILAK</a>) stock declined by 4.67% to $5.11. The company's market cap stands at $1.0 billion. </li>
<li>Motorsport Games (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSGM#NASDAQ">MSGM</a>) shares declined by 4.63% to $2.62. The market value of their outstanding shares is at $8.3 million. </li>
<li>Liberty Latin America (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LILA#NASDAQ">LILA</a>) stock fell 4.11% to $5.14. The company's market cap stands at $1.0 billion. </li>
<li>Moving iMage Technologies (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/MITQ#AMEX">MITQ</a>) shares fell 3.64% to $0.56. The company's market cap stands at $5.5 million. 
See Also: <a href="http://www.benzinga.com/money/best-communication-services-stocks/" title="www.benzinga.com/money/best-communication-services-stocks/">www.benzinga.com/money/best-communication-services-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ANTE

BAOS

BLMZ

CMLS

DRCT

LILA

LILAK

MITQ

MSGM

12 Communication Services Stocks Moving In Thursday's After-Market Session

<h3>Gainers</h3>
<ul>
<li>Forian (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FORA#NASDAQ">FORA</a>) shares rose 53.5% to $3.0 during Thursday's after-market session. The company's market cap stands at $93.5 million. </li>
<li>Exicure (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XCUR#NASDAQ">XCUR</a>) shares increased by 17.85% to $10.43. The market value of their outstanding shares is at $65.8 million. </li>
<li>Adicet Bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACET#NASDAQ">ACET</a>) shares moved upwards by 10.23% to $0.58. The company's market cap stands at $47.9 million. </li>
<li>Syra Health (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SYRA#NASDAQ">SYRA</a>) stock moved upwards by 9.02% to $0.11. The company's market cap stands at $1.3 million. </li>
<li>Ernexa Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ERNA#NASDAQ">ERNA</a>) shares moved upwards by 7.51% to $0.2. The market value of their outstanding shares is at $10.3 million. </li>
<li>X4 Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XFOR#NASDAQ">XFOR</a>) shares rose 7.44% to $0.2. The company's market cap stands at $35.6 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Adagio Medical Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADGM#NASDAQ">ADGM</a>) shares decreased by 13.5% to $1.54 during Thursday's after-market session. The market value of their outstanding shares is at $23.8 million. </li>
<li>China SXT Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SXTC#NASDAQ">SXTC</a>) shares declined by 9.96% to $1.9. The company's market cap stands at $26.1 million. </li>
<li>Clearside Biomedical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CLSD#NASDAQ">CLSD</a>) shares decreased by 6.97% to $0.8. The company's market cap stands at $60.6 million. </li>
<li>Sensei Biotherapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNSE#NASDAQ">SNSE</a>) shares decreased by 6.03% to $0.39. The market value of their outstanding shares is at $9.8 million. </li>
<li>Soleno Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SLNO#NASDAQ">SLNO</a>) shares decreased by 5.69% to $66.0. The market value of their outstanding shares is at $2.8 billion. </li>
<li>Hoth Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HOTH#NASDAQ">HOTH</a>) stock decreased by 5.59% to $0.75. The market value of their outstanding shares is at $9.8 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ACET

ADGM

CLSD

ERNA

FORA

HOTH

SLNO

SNSE

SXTC

SYRA

XCUR

XFOR

12 Health Care Stocks Moving In Thursday's After-Market Session

Motorsport Games Achieves Compliance With Nasdaq Listing Standards

Stock Split

FOXO

Foxo Technologies Announces 1 For 10 Reverse Stock Split, Effective April 28, 2025

Zoom Communications Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZM#NASDAQ">ZM</a>) shares are trading higher Thursday following a significant global outage that temporarily disabled key parts of Zoom's platform, including video calls,<a href="https://www.benzinga.com/quote/ZM/news"> its web portal and app.</a>
What To Know: The outage, which occurred on Wednesday afternoon, was confirmed by the company and tracked in real time by Downdetector.com, according to Reuters. At its peak, over 67,000 users reported problems accessing Zoom&#8217;s services, with disruptions affecting both U.S. and international users. The company did not offer a detailed technical explanation but confirmed on social media that full service had been restored.
The brief disruption likely reminded investors of the platform's broad user base and the technical risks that come with operating such a widely used service. But, the lack of a sharp sell-off suggests the market viewed the outage as temporary and not materially damaging to Zoom&#8217;s longer-term operations or reputation. Still, a repeat of such widespread failures could draw more scrutiny given how reliant businesses, schools and government agencies have become on Zoom for communication.
<h1 class="wp-block-heading">Will Zoom Shares Go Up?</h1>
When trying to assess whether or not Zoom will trade higher from current levels, it's a good idea to take a look at analyst forecasts.
Wall Street analysts have an average 12 month price target of $85.25 on Zoom. The &#8220;Street high&#8221; target is currently at $97 and the &#8220;Street low&#8221; target is $7. Of all the analysts covering Zoom Communications, five have positive ratings, seven have neutral ratings and none have negative ratings.
In the last month, four analysts have adjusted price targets. Here's a look at recent price target changes <a href="https://www.benzinga.com/quote/ZM/analyst-ratings">[Analyst Ratings]</a>. Benzinga also tracks Wall Street's most accurate analysts. Check out how analysts covering Zoom have performed in recent history.
Stocks don't move in a straight line. The average stock market return is approximately 10% per year. Zoom is down 12.37% year-to-date. The average analyst price target suggests the stock could have further upside ahead.
For a broad overview of everything you need to know about Zoom, visit <a href="https://www.benzinga.com/quote/ZM">here</a>. If you want to go above and beyond, there's no better tool to help you do just that than <a href="https://pro.benzinga.com/">Benzinga Pro</a>. Start your free trial today.
ZM Price Action: Zoom shares closed Thursday up 0.41% at $71.49 at the time of writing, according to<a href="https://pro.benzinga.com/dashboard?new_user=False&amp;backend=google-oauth2"> Benzinga Pro.</a>
<figure class="wp-block-image size-large is-resized"><a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0417"><img loading="lazy" decoding="async" width="1024" height="566" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/17163518/Screenshot-2025-04-17-at-16.33.21-1024x566.png" alt="" class="wp-image-877718" style="width:425px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/17163518/Screenshot-2025-04-17-at-16.33.21-1024x566.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/17163518/Screenshot-2025-04-17-at-16.33.21-300x166.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/17163518/Screenshot-2025-04-17-at-16.33.21-768x425.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/17163518/Screenshot-2025-04-17-at-16.33.21.png 1457w" sizes="(max-width: 1024px) 100vw, 1024px" /></a></figure>
Read Next:
<ul>
<li><a href="https://www.benzinga.com/economics/macro-economic-events/25/04/44875406/hell-be-out-if-i-ask-him-can-trumps-threat-to-oust-powell-shake-the-fed">&#8216;He&#8217;ll Be Out&#8230; If I Ask Him&#8217;: Can Trump&#8217;s Threat To Oust Powell Shake The Fed?</a></li>
</ul>
Photo: Shutterstock.

What's Going On With Zoom Shares Today?

Analysts' ratings for Take-Two Interactive (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TTWO#NASDAQ">TTWO</a>) over the last quarter vary from bullish to bearish, as provided by 11 analysts.
The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">6</td>
<td align="right">4</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">4</td>
<td align="right">3</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Insights from analysts' 12-month price targets are revealed, presenting an average target of $223.45, a high estimate of $270.00, and a low estimate of $170.00. Observing a 14.71% increase, the current average has risen from the previous average price target of $194.80. 
<img src="https://www.benzinga.com/files/images/story/2025/1744923677_0.png" alt="price target chart" />
<h2>Breaking Down Analyst Ratings: A Detailed Examination</h2>
In examining recent analyst actions, we gain insights into how financial experts perceive Take-Two Interactive. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
&#x7C; Analyst &#x7C; Analyst Firm &#x7C; Action Taken &#x7C; Rating &#x7C;Current Price Target&#x7C; Prior Price Target &#x7C; 
&#x7C;--------------------&#x7C;--------------------&#x7C;---------------&#x7C;---------------&#x7C;--------------------&#x7C;--------------------&#x7C; 
&#x7C;Brian Nowak &#x7C;Morgan Stanley &#x7C;Lowers &#x7C;Overweight &#x7C; $210.00&#x7C;$215.00 &#x7C; 
&#x7C;Edward Woo &#x7C;Ascendiant Capital &#x7C;Raises &#x7C;Buy &#x7C; $270.00&#x7C;$172.00 &#x7C; 
&#x7C;Wyatt Swanson &#x7C;DA Davidson &#x7C;Announces &#x7C;Buy &#x7C; $250.00&#x7C;- &#x7C; 
&#x7C;Michael Pachter &#x7C;Wedbush &#x7C;Maintains &#x7C;Outperform &#x7C; $215.00&#x7C;$215.00 &#x7C; 
&#x7C;Mike Hickey &#x7C;Benchmark &#x7C;Raises &#x7C;Buy &#x7C; $225.00&#x7C;$210.00 &#x7C; 
&#x7C;Eric Sheridan &#x7C;Goldman Sachs &#x7C;Raises &#x7C;Buy &#x7C; $230.00&#x7C;$205.00 &#x7C; 
&#x7C;Andrew Marok &#x7C;Raymond James &#x7C;Raises &#x7C;Outperform &#x7C; $220.00&#x7C;$190.00 &#x7C; 
&#x7C;Clay Griffin &#x7C;MoffettNathanson &#x7C;Raises &#x7C;Neutral &#x7C; $170.00&#x7C;$156.00 &#x7C; 
&#x7C;Christopher Schoell &#x7C;UBS &#x7C;Raises &#x7C;Buy &#x7C; $230.00&#x7C;$175.00 &#x7C; 
&#x7C;Martin Yang &#x7C;Oppenheimer &#x7C;Raises &#x7C;Outperform &#x7C; $215.00&#x7C;$190.00 &#x7C; 
&#x7C;Drew Crum &#x7C;Stifel &#x7C;Raises &#x7C;Buy &#x7C; $223.00&#x7C;$220.00 &#x7C;
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Take-Two Interactive. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li>Rating: Analysts unravel qualitative evaluations for stocks, ranging from 'Outperform' to 'Underperform'. These ratings offer insights into expectations for the relative performance of Take-Two Interactive compared to the broader market.</li>
<li>Price Targets: Analysts gauge the dynamics of price targets, providing estimates for the future value of Take-Two Interactive's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
For valuable insights into Take-Two Interactive's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/TTWO/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Take-Two Interactive analyst ratings.</a>
<h2>Discovering Take-Two Interactive: A Closer Look</h2>
Take-Two is one of the largest global developers and publishers of video games, with labels including Rockstar, 2K, and Zynga. Grand Theft Auto is the firm's biggest franchise, accounting for about 30% of total sales for the past decade. NBA 2K is the industry's dominant basketball video game, with Take-Two releasing a new version annually. Other notable franchises include Red Dead Redemption, Borderlands, and Civilization. Typically, more than three quarters of the firm's sales are from in-game spending, with the remainder coming from initial game sales. Since acquiring Zynga in 2022, mobile makes up about half of total sales.
<h3>Unraveling the Financial Story of Take-Two Interactive</h3>
Market Capitalization: Exceeding industry standards, the company's market capitalization places it above industry average in size relative to peers. This emphasizes its significant scale and robust market position.
Decline in Revenue: Over the 3M period, Take-Two Interactive faced challenges, resulting in a decline of approximately -0.48% in revenue growth as of 31 December, 2024. This signifies a reduction in the company's top-line earnings. As compared to competitors, the company surpassed expectations with a growth rate higher than the average among peers in the Communication Services sector.
Net Margin: Take-Two Interactive's net margin excels beyond industry benchmarks, reaching -9.21%. This signifies efficient cost management and strong financial health.
Return on Equity (ROE): Take-Two Interactive's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of -2.18%, the company showcases efficient use of equity capital and strong financial health.
Return on Assets (ROA): Take-Two Interactive's financial strength is reflected in its exceptional ROA, which exceeds industry averages. With a remarkable ROA of -0.97%, the company showcases efficient use of assets and strong financial health.
Debt Management: Take-Two Interactive's debt-to-equity ratio is below the industry average at 0.72, reflecting a lower dependency on debt financing and a more conservative financial approach.
<h2>Analyst Ratings: Simplified</h2>
Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Analyst Ratings

TTWO

Deep Dive Into Take-Two Interactive Stock: Analyst Perspectives (11 Ratings)

4 analysts have shared their evaluations of Applied Industrial Techs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AIT#NYSE">AIT</a>) during the recent three months, expressing a mix of bullish and bearish perspectives.
The table below provides a concise overview of recent ratings by analysts, offering insights into the changing sentiments over the past 30 days and drawing comparisons with the preceding months for a holistic perspective.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">1</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $276.25, with a high estimate of $290.00 and a low estimate of $265.00. Observing a downward trend, the current average is 3.49% lower than the prior average price target of $286.25. 
<img src="https://www.benzinga.com/files/images/story/2025/1744923670_0.png" alt="price target chart" />
<h2>Diving into Analyst Ratings: An In-Depth Exploration</h2>
In examining recent analyst actions, we gain insights into how financial experts perceive Applied Industrial Techs. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
&#x7C; Analyst &#x7C; Analyst Firm &#x7C; Action Taken &#x7C; Rating &#x7C;Current Price Target&#x7C; Prior Price Target &#x7C; 
&#x7C;--------------------&#x7C;--------------------&#x7C;---------------&#x7C;---------------&#x7C;--------------------&#x7C;--------------------&#x7C; 
&#x7C;Chris Dankert &#x7C;Loop Capital &#x7C;Lowers &#x7C;Buy &#x7C; $290.00&#x7C;$320.00 &#x7C; 
&#x7C;Ken Newman &#x7C;Keybanc &#x7C;Lowers &#x7C;Overweight &#x7C; $275.00&#x7C;$325.00 &#x7C; 
&#x7C;David Manthey &#x7C;Baird &#x7C;Raises &#x7C;Outperform &#x7C; $275.00&#x7C;$250.00 &#x7C; 
&#x7C;Sam Darkatsh &#x7C;Raymond James &#x7C;Raises &#x7C;Outperform &#x7C; $265.00&#x7C;$250.00 &#x7C;
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Applied Industrial Techs. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Providing a comprehensive analysis, analysts offer qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Applied Industrial Techs compared to the broader market.</li>
<li>Price Targets: Gaining insights, analysts provide estimates for the future value of Applied Industrial Techs's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of Applied Industrial Techs's market position. Stay informed and make well-informed decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/AIT/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Applied Industrial Techs analyst ratings.</a>
<h2>Discovering Applied Industrial Techs: A Closer Look</h2>
Applied Industrial Technologies Inc is a distributor of industrial products to the maintenance, repair, and operations market and the original equipment manufacturing industry. Further, the company provides engineering and design services for industrial and fluid power applications. The products include bearings, power transmission components, fluid power components and systems, industrial rubber products, linear motion components, safety products, oilfield supplies, and other industrial and maintenance supplies. The company's reportable segments are; Service Center Based Distribution which derives key revenue, and Engineered Solutions. Geographically, the company derives its key revenue from the United States and the rest from Canada and other countries.
<h3>Financial Milestones: Applied Industrial Techs's Journey</h3>
Market Capitalization Analysis: Below industry benchmarks, the company's market capitalization reflects a smaller scale relative to peers. This could be attributed to factors such as growth expectations or operational capacity.
Revenue Growth: Applied Industrial Techs's revenue growth over a period of 3M has faced challenges. As of 31 December, 2024, the company experienced a revenue decline of approximately -0.39%. This indicates a decrease in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Industrials sector.
Net Margin: Applied Industrial Techs's net margin is impressive, surpassing industry averages. With a net margin of 8.69%, the company demonstrates strong profitability and effective cost management.
Return on Equity (ROE): Applied Industrial Techs's ROE falls below industry averages, indicating challenges in efficiently using equity capital. With an ROE of 5.26%, the company may face hurdles in generating optimal returns for shareholders.
Return on Assets (ROA): Applied Industrial Techs's ROA excels beyond industry benchmarks, reaching 3.09%. This signifies efficient management of assets and strong financial health.
Debt Management: Applied Industrial Techs's debt-to-equity ratio is below the industry average. With a ratio of 0.32, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.
<h2>The Significance of Analyst Ratings Explained</h2>
Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.
Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Where Applied Industrial Techs Stands With Analysts

Digital Realty Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DLR#NYSE">DLR</a>) underwent analysis by 12 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish.
The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">2</td>
<td align="right">8</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">5</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $195.5, along with a high estimate of $220.00 and a low estimate of $139.00. A negative shift in sentiment is evident as analysts have decreased the average price target by 2.03%. 
<img src="https://www.benzinga.com/files/images/story/2025/1744923659_0.png" alt="price target chart" />
<h2>Interpreting Analyst Ratings: A Closer Look</h2>
A clear picture of Digital Realty Trust's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
&#x7C; Analyst &#x7C; Analyst Firm &#x7C; Action Taken &#x7C; Rating &#x7C;Current Price Target&#x7C; Prior Price Target &#x7C; 
&#x7C;--------------------&#x7C;--------------------&#x7C;---------------&#x7C;-----------------&#x7C;--------------------&#x7C;--------------------&#x7C; 
&#x7C;Michael Rollins &#x7C;Citigroup &#x7C;Lowers &#x7C;Buy &#x7C; $174.00&#x7C;$188.00 &#x7C; 
&#x7C;Omotayo Okusanya &#x7C;Mizuho &#x7C;Lowers &#x7C;Outperform &#x7C; $177.00&#x7C;$211.00 &#x7C; 
&#x7C;Brendan Lynch &#x7C;Barclays &#x7C;Lowers &#x7C;Underweight &#x7C; $139.00&#x7C;$142.00 &#x7C; 
&#x7C;Anthony Hau &#x7C;Truist Securities &#x7C;Lowers &#x7C;Buy &#x7C; $185.00&#x7C;$201.00 &#x7C; 
&#x7C;Greg Miller &#x7C;JMP Securities &#x7C;Maintains &#x7C;Market Outperform&#x7C; $220.00&#x7C;$220.00 &#x7C; 
&#x7C;Maher Yaghi &#x7C;Scotiabank &#x7C;Announces &#x7C;Sector Outperform&#x7C; $208.00&#x7C;- &#x7C; 
&#x7C;Greg Miller &#x7C;JMP Securities &#x7C;Maintains &#x7C;Market Outperform&#x7C; $220.00&#x7C;$220.00 &#x7C; 
&#x7C;Richard Choe &#x7C;JP Morgan &#x7C;Raises &#x7C;Overweight &#x7C; $190.00&#x7C;$185.00 &#x7C; 
&#x7C;Greg Miller &#x7C;JMP Securities &#x7C;Maintains &#x7C;Market Outperform&#x7C; $220.00&#x7C;$220.00 &#x7C; 
&#x7C;Eric Luebchow &#x7C;Wells Fargo &#x7C;Lowers &#x7C;Overweight &#x7C; $185.00&#x7C;$210.00 &#x7C; 
&#x7C;Greg Miller &#x7C;JMP Securities &#x7C;Maintains &#x7C;Market Outperform&#x7C; $220.00&#x7C;$220.00 &#x7C; 
&#x7C;Maher Yaghi &#x7C;Scotiabank &#x7C;Raises &#x7C;Sector Perform &#x7C; $208.00&#x7C;$178.00 &#x7C;
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Digital Realty Trust. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Analyzing trends, analysts offer qualitative evaluations, ranging from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Digital Realty Trust compared to the broader market.</li>
<li>Price Targets: Delving into movements, analysts provide estimates for the future value of Digital Realty Trust's stock. This analysis reveals shifts in analysts' expectations over time.</li>
</ul>
For valuable insights into Digital Realty Trust's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/DLR/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Digital Realty Trust analyst ratings.</a>
<h2>All You Need to Know About Digital Realty Trust</h2>
Digital Realty owns and operates over 300 data centers worldwide. It has nearly 40 million rentable square feet across five continents. Digital's offerings range from retail co-location, where an enterprise may rent a single cabinet and rely on Digital to provide all the accommodations, to "cold shells," where hyperscale cloud service providers can simply rent much, or all, of a barren, power-connected building. In recent years, Digital Realty has de-emphasized cold shells and now primarily provides higher-level service to tenants, which outsource their related IT needs to Digital. The company operates as a real estate investment trust.
<h3>Digital Realty Trust's Economic Impact: An Analysis</h3>
Market Capitalization Analysis: The company's market capitalization surpasses industry averages, showcasing a dominant size relative to peers and suggesting a strong market position.
Revenue Growth: Over the 3M period, Digital Realty Trust showcased positive performance, achieving a revenue growth rate of 4.84% as of 31 December, 2024. This reflects a substantial increase in the company's top-line earnings. When compared to others in the Real Estate sector, the company excelled with a growth rate higher than the average among peers.
Net Margin: Digital Realty Trust's net margin falls below industry averages, indicating challenges in achieving strong profitability. With a net margin of 12.49%, the company may face hurdles in effective cost management.
Return on Equity (ROE): Digital Realty Trust's ROE is below industry standards, pointing towards difficulties in efficiently utilizing equity capital. With an ROE of 0.87%, the company may encounter challenges in delivering satisfactory returns for shareholders.
Return on Assets (ROA): Digital Realty Trust's ROA is below industry standards, pointing towards difficulties in efficiently utilizing assets. With an ROA of 0.4%, the company may encounter challenges in delivering satisfactory returns from its assets.
Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 0.87.
<h2>Analyst Ratings: What Are They?</h2>
Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.
Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

The Analyst Verdict: Digital Realty Trust In The Eyes Of 12 Experts

In the current market session, UBS Gr Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UBS#NYSE">UBS</a>) price is at $27.94, after a 0.47% spike. However, over the past month, the stock decreased by 15.31%, and in the past year, by 0.43%. Shareholders might be interested in knowing whether the stock is undervalued, even if the company is performing up to par in the current session. 

<img src="https://www.benzinga.com/files/images/story/2025/1744923653_0.png" alt="Past Year Chart" />

<h3>UBS Gr P/E Ratio Analysis in Relation to Industry Peers</h3>
The P/E ratio measures the current share price to the company's EPS. It is used by long-term investors to analyze the company's current performance against it's past earnings, historical data and aggregate market data for the industry or the indices, such as S&amp;P 500. A higher P/E indicates that investors expect the company to perform better in the future, and the stock is probably overvalued, but not necessarily. It also could indicate that investors are willing to pay a higher share price currently, because they expect the company to perform better in the upcoming quarters. This leads investors to also remain optimistic about rising dividends in the future. 
Compared to the aggregate P/E ratio of the 31.5 in the Capital Markets industry, UBS Gr Inc. has a lower P/E ratio of 18.3. Shareholders might be inclined to think that the stock might perform worse than it's industry peers. It's also possible that the stock is undervalued. 

<img src="https://www.benzinga.com/files/images/story/2025/1744923653_1.png" alt="Guage" />

In summary, while the price-to-earnings ratio is a valuable tool for investors to evaluate a company's market performance, it should be used with caution. A low P/E ratio can be an indication of undervaluation, but it can also suggest weak growth prospects or financial instability. Moreover, the P/E ratio is just one of many metrics that investors should consider when making investment decisions, and it should be evaluated alongside other financial ratios, industry trends, and qualitative factors. By taking a comprehensive approach to analyzing a company's financial health, investors can make well-informed decisions that are more likely to lead to successful outcomes.

Intraday Update

Price Over Earnings Overview: UBS Gr

5 analysts have expressed a variety of opinions on Vir Biotechnology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VIR#NASDAQ">VIR</a>) over the past quarter, offering a diverse set of opinions from bullish to bearish.
Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">4</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Insights from analysts' 12-month price targets are revealed, presenting an average target of $58.2, a high estimate of $110.00, and a low estimate of $19.00. This current average represents a 0.68% decrease from the previous average price target of $58.60. 
<img src="https://www.benzinga.com/files/images/story/2025/1744923641_0.png" alt="price target chart" />
<h2>Exploring Analyst Ratings: An In-Depth Overview</h2>
The analysis of recent analyst actions sheds light on the perception of Vir Biotechnology by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
&#x7C; Analyst &#x7C; Analyst Firm &#x7C; Action Taken &#x7C; Rating &#x7C;Current Price Target&#x7C; Prior Price Target &#x7C; 
&#x7C;--------------------&#x7C;--------------------&#x7C;---------------&#x7C;---------------&#x7C;--------------------&#x7C;--------------------&#x7C; 
&#x7C;Paul Choi &#x7C;Goldman Sachs &#x7C;Lowers &#x7C;Buy &#x7C; $21.00&#x7C;$28.00 &#x7C; 
&#x7C;Gena Wang &#x7C;Barclays &#x7C;Raises &#x7C;Overweight &#x7C; $31.00&#x7C;$26.00 &#x7C; 
&#x7C;Patrick Trucchio &#x7C;HC Wainwright &amp; Co. &#x7C;Maintains &#x7C;Buy &#x7C; $110.00&#x7C;$110.00 &#x7C; 
&#x7C;Joseph Stringer &#x7C;Needham &#x7C;Maintains &#x7C;Buy &#x7C; $19.00&#x7C;$19.00 &#x7C; 
&#x7C;Patrick Trucchio &#x7C;HC Wainwright &amp; Co. &#x7C;Maintains &#x7C;Buy &#x7C; $110.00&#x7C;$110.00 &#x7C;
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Vir Biotechnology. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Providing a comprehensive analysis, analysts offer qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Vir Biotechnology compared to the broader market.</li>
<li>Price Targets: Analysts predict movements in price targets, offering estimates for Vir Biotechnology's future value. Examining the current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of Vir Biotechnology's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/VIR/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Vir Biotechnology analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">you can start by tracking it here</a>.
<h2>Discovering Vir Biotechnology: A Closer Look</h2>
Vir Biotechnology Inc is an immunology company focused on combining cutting-edge technologies to treat and prevent serious infectious diseases and other serious conditions, including viral-associated diseases. Through internal development, collaborations, and acquisitions, it has four technology platforms, focused on antibodies, T cells, innate immunity, and small interfering ribonucleic acid, or siRNA. The company's pipeline consists of product candidates targeting hepatitis B, HBV, influenza A, human immunodeficiency virus, HIV, and tuberculosis, or TB. Its revenue sources are collaboration revenue, contract revenue, grant revenue, and license revenue.
<h3>A Deep Dive into Vir Biotechnology's Financials</h3>
Market Capitalization Analysis: The company's market capitalization is above the industry average, indicating that it is relatively larger in size compared to peers. This may suggest a higher level of investor confidence and market recognition.
Positive Revenue Trend: Examining Vir Biotechnology's financials over 3M reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 17.45% as of 31 December, 2024, showcasing a substantial increase in top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Health Care sector.
Net Margin: Vir Biotechnology's net margin excels beyond industry benchmarks, reaching -927.37%. This signifies efficient cost management and strong financial health.
Return on Equity (ROE): Vir Biotechnology's ROE stands out, surpassing industry averages. With an impressive ROE of -8.75%, the company demonstrates effective use of equity capital and strong financial performance.
Return on Assets (ROA): The company's ROA is a standout performer, exceeding industry averages. With an impressive ROA of -7.22%, the company showcases effective utilization of assets.
Debt Management: Vir Biotechnology's debt-to-equity ratio is below the industry average at 0.09, reflecting a lower dependency on debt financing and a more conservative financial approach.
<h2>The Significance of Analyst Ratings Explained</h2>
Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.
Beyond their standard evaluations, some analysts contribute predictions for metrics like growth estimates, earnings, and revenue, furnishing investors with additional guidance. Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

5 Analysts Have This To Say About Vir Biotechnology

7 analysts have shared their evaluations of Edgewell Personal Care (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EPC#NYSE">EPC</a>) during the recent three months, expressing a mix of bullish and bearish perspectives.
The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">3</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $34.29, with a high estimate of $43.00 and a low estimate of $28.00. Observing a downward trend, the current average is 10.09% lower than the prior average price target of $38.14. 
<img src="https://www.benzinga.com/files/images/story/2025/1744923621_0.png" alt="price target chart" />
<h2>Exploring Analyst Ratings: An In-Depth Overview</h2>
The standing of Edgewell Personal Care among financial experts is revealed through an in-depth exploration of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
&#x7C; Analyst &#x7C; Analyst Firm &#x7C; Action Taken &#x7C; Rating &#x7C;Current Price Target&#x7C; Prior Price Target &#x7C; 
&#x7C;--------------------&#x7C;--------------------&#x7C;---------------&#x7C;---------------&#x7C;--------------------&#x7C;--------------------&#x7C; 
&#x7C;Peter Grom &#x7C;UBS &#x7C;Raises &#x7C;Neutral &#x7C; $32.00&#x7C;$31.00 &#x7C; 
&#x7C;Lauren Lieberman &#x7C;Barclays &#x7C;Lowers &#x7C;Equal-Weight &#x7C; $28.00&#x7C;$30.00 &#x7C; 
&#x7C;Susan Anderson &#x7C;Canaccord Genuity &#x7C;Lowers &#x7C;Buy &#x7C; $40.00&#x7C;$53.00 &#x7C; 
&#x7C;Lauren Lieberman &#x7C;Barclays &#x7C;Lowers &#x7C;Equal-Weight &#x7C; $30.00&#x7C;$33.00 &#x7C; 
&#x7C;Nik Modi &#x7C;RBC Capital &#x7C;Lowers &#x7C;Outperform &#x7C; $43.00&#x7C;$48.00 &#x7C; 
&#x7C;Chris Carey &#x7C;Wells Fargo &#x7C;Lowers &#x7C;Overweight &#x7C; $35.00&#x7C;$37.00 &#x7C; 
&#x7C;Dara Mohsenian &#x7C;Morgan Stanley &#x7C;Lowers &#x7C;Underweight &#x7C; $32.00&#x7C;$35.00 &#x7C;
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Edgewell Personal Care. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analysts unravel qualitative evaluations for stocks, ranging from 'Outperform' to 'Underperform'. These ratings offer insights into expectations for the relative performance of Edgewell Personal Care compared to the broader market.</li>
<li>Price Targets: Delving into movements, analysts provide estimates for the future value of Edgewell Personal Care's stock. This analysis reveals shifts in analysts' expectations over time.</li>
</ul>
For valuable insights into Edgewell Personal Care's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/EPC/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Edgewell Personal Care analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">you can start by tracking it here</a>.
<h2>Discovering Edgewell Personal Care: A Closer Look</h2>
Edgewell Personal Care Co is a personal-care company. The operating segments of the company include Wet Shave, Sun and Skin Care and Feminine Care. Some of the brands offered by the company include Edge, Skintimate, Personna, Schick, Carefree, Playtex, Banana Boat and Hawaiian Tropic. It derives a majority of its revenue from the United States.
<h3>Understanding the Numbers: Edgewell Personal Care's Finances</h3>
Market Capitalization Analysis: The company's market capitalization is below the industry average, suggesting that it is relatively smaller compared to peers. This could be due to various factors, including perceived growth potential or operational scale.
Revenue Challenges: Edgewell Personal Care's revenue growth over 3M faced difficulties. As of 31 December, 2024, the company experienced a decline of approximately -2.15%. This indicates a decrease in top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Consumer Staples sector.
Net Margin: Edgewell Personal Care's net margin is below industry averages, indicating potential challenges in maintaining strong profitability. With a net margin of -0.44%, the company may face hurdles in effective cost management.
Return on Equity (ROE): Edgewell Personal Care's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive -0.14% ROE, the company effectively utilizes shareholder equity capital.
Return on Assets (ROA): Edgewell Personal Care's ROA is below industry averages, indicating potential challenges in efficiently utilizing assets. With an ROA of -0.06%, the company may face hurdles in achieving optimal financial returns.
Debt Management: Edgewell Personal Care's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 0.98.
<h2>The Core of Analyst Ratings: What Every Investor Should Know</h2>
Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.
In addition to their assessments, some analysts extend their insights by offering predictions for key metrics such as earnings, revenue, and growth estimates. This supplementary information provides further guidance for traders. It is crucial to recognize that, despite their specialization, analysts are human and can only provide forecasts based on their beliefs.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Demystifying Edgewell Personal Care: Insights From 7 Analyst Reviews

Across the recent three months, 6 analysts have shared their insights on Bruker (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BRKR#NASDAQ">BRKR</a>), expressing a variety of opinions spanning from bullish to bearish.
The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">1</td>
<td align="right">4</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $57.0, with a high estimate of $65.00 and a low estimate of $50.00. Observing a downward trend, the current average is 17.39% lower than the prior average price target of $69.00. 
<img src="https://www.benzinga.com/files/images/story/2025/1744923614_0.png" alt="price target chart" />
<h2>Deciphering Analyst Ratings: An In-Depth Analysis</h2>
The standing of Bruker among financial experts is revealed through an in-depth exploration of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
&#x7C; Analyst &#x7C; Analyst Firm &#x7C; Action Taken &#x7C; Rating &#x7C;Current Price Target&#x7C; Prior Price Target &#x7C; 
&#x7C;--------------------&#x7C;--------------------&#x7C;---------------&#x7C;---------------&#x7C;--------------------&#x7C;--------------------&#x7C; 
&#x7C;Brandon Couillard &#x7C;Wells Fargo &#x7C;Lowers &#x7C;Overweight &#x7C; $60.00&#x7C;$75.00 &#x7C; 
&#x7C;Luke Sergott &#x7C;Barclays &#x7C;Lowers &#x7C;Overweight &#x7C; $50.00&#x7C;$60.00 &#x7C; 
&#x7C;Patrick Donnelly &#x7C;Citigroup &#x7C;Lowers &#x7C;Buy &#x7C; $50.00&#x7C;$75.00 &#x7C; 
&#x7C;Daniel Arias &#x7C;Stifel &#x7C;Lowers &#x7C;Hold &#x7C; $57.00&#x7C;$70.00 &#x7C; 
&#x7C;Luke Sergott &#x7C;Barclays &#x7C;Lowers &#x7C;Overweight &#x7C; $60.00&#x7C;$65.00 &#x7C; 
&#x7C;Luke Sergott &#x7C;Barclays &#x7C;Lowers &#x7C;Overweight &#x7C; $65.00&#x7C;$69.00 &#x7C;
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Bruker. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analysts unravel qualitative evaluations for stocks, ranging from 'Outperform' to 'Underperform'. These ratings offer insights into expectations for the relative performance of Bruker compared to the broader market.</li>
<li>Price Targets: Delving into movements, analysts provide estimates for the future value of Bruker's stock. This analysis reveals shifts in analysts' expectations over time.</li>
</ul>
Capture valuable insights into Bruker's market standing by understanding these analyst evaluations alongside pertinent financial indicators. Stay informed and make strategic decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/BRKR/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Bruker analyst ratings.</a>
<h2>Delving into Bruker's Background</h2>
Bruker Corp manufactures scientific instruments and diagnostic tests for customers in the life sciences, applied markets, pharmaceutical, and biotechnology industries. The company operates in segments, namely, Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Supercon Technologies (BEST). The company generates maximum revenue from the BSI CALID segment. Geographically, it derives the maximum of its revenue from United States.
<h3>Key Indicators: Bruker's Financial Health</h3>
Market Capitalization Analysis: Positioned below industry benchmarks, the company's market capitalization faces constraints in size. This could be influenced by factors such as growth expectations or operational capacity.
Revenue Growth: Over the 3M period, Bruker showcased positive performance, achieving a revenue growth rate of 14.64% as of 31 December, 2024. This reflects a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company stands out with a growth rate higher than the average among peers in the Health Care sector.
Net Margin: Bruker's net margin excels beyond industry benchmarks, reaching 1.4%. This signifies efficient cost management and strong financial health.
Return on Equity (ROE): Bruker's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of 0.76%, the company showcases efficient use of equity capital and strong financial health.
Return on Assets (ROA): Bruker's ROA excels beyond industry benchmarks, reaching 0.23%. This signifies efficient management of assets and strong financial health.
Debt Management: Bruker's debt-to-equity ratio is notably higher than the industry average. With a ratio of 1.26, the company relies more heavily on borrowed funds, indicating a higher level of financial risk.
<h2>Understanding the Relevance of Analyst Ratings</h2>
Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.
Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.
Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

BRKR

A Glimpse Into The Expert Outlook On Bruker Through 6 Analysts

Cencora (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/COR#NYSE">COR</a>) has outperformed the market over the past 10 years by 9.42% on an annualized basis producing an average annual return of 19.01%. Currently, Cencora has a market capitalization of $55.54 billion. 
Buying $1000 In COR: If an investor had bought $1000 of COR stock 10 years ago, it would be worth $5,708.54 today based on a price of $286.70 for COR at the time of writing.
<h3>Cencora's Performance Over Last 10 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1744923611_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Here's How Much You Would Have Made Owning Cencora Stock In The Last 10 Years

Press Releases

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates ACCD, AVAV, VCSA, AMCR on Behalf of Shareholders

Legal

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates ENFN, FNA, LGTY, ACCD on Behalf of Shareholders

Small Cap

$HAREHOLDER ALERT: The M&A Class Action Firm Continues To Investigate The Merger - YOTA, PORT, ACCD, ESSA

Transcarent and Accolade Announce Expiration of Hart-Scott Rodino Waiting Period for Pending Merger Transaction

ACCD Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Accolade, Inc. Is Fair to Shareholders

Accolade Welcomes Oshi Health to Trusted Partner Ecosystem

STOCKHOLDER ALERT: The M&A Class Action Firm Encourages Shareholders of ACCD, SKGR, AVAV, WMPN to Act Now

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates VOXX, ACCD, WMPN, AVAV on Behalf of Shareholders

Comments

Accolade Inc Ordinary Shares

Accolade Inc Ordinary Shares (ACCD) Opciones

No option chain data available. Please try again later

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL